{"component": "clause", "props": {"groups": [{"snippet": "2 Ukon\u010den\u00ed platnosti Sponsor may terminate this Agreement for any reason effective immediately upon written notice to Institution. Site may terminate this Agreement upon written notice to Sponsor and CRO if circumstances beyond Site\u2019s reasonable control prevent completion of the Study, or if it reasonably determines that it is unsafe to continue the Study. Upon receipt of notice of termination, Site shall immediately cease all recruitment, follow the specified termination procedures, ensure that any required Study Subject follow-up procedures are completed, and make all reasonable efforts to minimize further costs, and DrugDev shall make a final payment for visits or milestones Zadavatel je opr\u00e1vn\u011bn ukon\u010dit platnost t\u00e9to Smlouvy z jak\u00e9hokoli d\u016fvodu s okam\u017eitou \u00fa\u010dinnost\u00ed neprodlen\u011b na z\u00e1klad\u011b doru\u010den\u00ed p\u00edsemn\u00e9ho ozn\u00e1men\u00ed. M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed je opr\u00e1vn\u011bno ukon\u010dit platnost t\u00e9to Smlouvy p\u00edsemn\u00fdm ozn\u00e1men\u00edm Zadavateli a CRO v p\u0159\u00edpad\u011b, \u017ee okolnosti, je\u017e jsou svoj\u00ed povahou mimo mo\u017enost ovlivn\u011bn\u00ed ze strany M\u00edsta prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed, zabr\u00e1n\u00ed dokon\u010den\u00ed Studie, nebo v p\u0159\u00edpad\u011b, \u017ee M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed d\u016fvodn\u011b usoud\u00ed, \u017ee pokra\u010dov\u00e1n\u00ed ve Studii nen\u00ed bezpe\u010dn\u00e9. V n\u00e1vaznosti na doru\u010den\u00ed ozn\u00e1men\u00ed o ukon\u010den\u00ed platnosti M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed neprodlen\u011b ukon\u010d\u00ed jak\u00fdkoli n\u00e1bor subjekt\u016f, properly performed pursuant to this Agreement in the amounts specified in Attachment A; provided, however, Payments will be in each case reduced by ten (10 %) percent. This reduced amount shall represent a value of any/all activities related to close- out of the database, and will be made upon the final acceptance by Sponsor of all CRF pages and all data queries issued and satisfaction of all other applicable conditions set forth herein. If a material breach of this Agreement appears to have occurred and termination may be required, then, except to the extent that Study Subject safety may be jeopardized, Sponsor may suspend performance of all or part of this Agreement, including, but not limited to, subject enrollment. bude jednat v souladu s definovan\u00fdmi postupy pro ukon\u010den\u00ed, zajist\u00ed, \u017ee ve vztahu k subjekt\u016fm Studie budou dokon\u010deny jak\u00e9koli procesy kontroln\u00ed povahy, a vyvinou nezbytn\u00e9 \u00fasil\u00ed za \u00fa\u010delem limitace jak\u00fdchkoli dal\u0161\u00edch n\u00e1klad\u016f, p\u0159i\u010dem\u017e DrugDev provede z\u00e1v\u011bre\u010dnou \u00fahradu za n\u00e1v\u0161t\u011bvy a miln\u00edky, je\u017e byly \u0159\u00e1dn\u011b provedeny na z\u00e1klad\u011b a v souladu s touto Smlouvou, a to ve v\u00fd\u0161i \u010d\u00e1stek definovan\u00fdch v P\u0159\u00edloze A; av\u0161ak za podm\u00ednky, \u017ee Platby budou v ka\u017ed\u00e9m p\u0159\u00edpad\u011b sn\u00ed\u017eeny o \u010d\u00e1stku ve v\u00fd\u0161i deseti (10 %) procent. Takto sn\u00ed\u017een\u00e1 \u010d\u00e1stka bude p\u0159edstavovat hodnotu ve\u0161ker\u00fdch \u010dinnost\u00ed spojen\u00fdch s uzav\u0159en\u00edm datab\u00e1ze, a bude poskytnuta pot\u00e9, co Zadavatel schv\u00e1l\u00ed ve\u0161ker\u00e9 str\u00e1nky formul\u00e1\u0159\u016f CRF, a d\u00e1le pot\u00e9, co budou poskytnuta ve\u0161ker\u00e1 vyjasn\u011bn\u00ed dat a d\u00e1le dojde ke spln\u011bn\u00ed ve\u0161ker\u00fdch ostatn\u00edch podm\u00ednek, je\u017e jsou stanoveny v t\u00e9to Smlouv\u011b. V p\u0159\u00edpad\u011b, \u017ee dojde ke vzniku domn\u011bn\u00ed, \u017ee do\u0161lo k podstatn\u00e9mu poru\u0161en\u00ed t\u00e9to Smlouvy a m\u016f\u017ee tak doj\u00edt k ukon\u010den\u00ed platnosti t\u00e9to Smlouvy, pak s v\u00fdjimkou a \u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587 \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587 ohro\u017eena bezpe\u010dnost Subjekt\u016f studie, Zadavatel m\u016f\u017ee p\u0159eru\u0161it napln\u011bn\u00ed cel\u00e9 \u010di \u010d\u00e1sti t\u00e9to Smlouvy, zejm\u00e9na v\u010detn\u011b za\u0159azov\u00e1n\u00ed Subjekt\u016f studie.", "snippet_links": [{"key": "ukon\u010den\u00ed-platnosti", "type": "clause", "offset": [2, 20]}, {"key": "for-any-reason", "type": "clause", "offset": [58, 72]}, {"key": "notice-to", "type": "definition", "offset": [108, 117]}, {"key": "reasonable-control", "type": "clause", "offset": [235, 253]}, {"key": "completion-of-the-study", "type": "clause", "offset": [262, 285]}, {"key": "notice-of-termination", "type": "clause", "offset": [375, 396]}, {"key": "termination-procedures", "type": "clause", "offset": [465, 487]}, {"key": "study-subject", "type": "clause", "offset": [514, 527]}, {"key": "efforts-to-minimize", "type": "clause", "offset": [588, 607]}, {"key": "further-costs", "type": "clause", "offset": [608, 621]}, {"key": "payment-for", "type": "clause", "offset": [654, 665]}, {"key": "prov\u00e1d\u011bn\u00ed-klinick\u00e9ho-hodnocen\u00ed", "type": "clause", "offset": [838, 868]}, {"key": "dokon\u010den\u00ed-studie", "type": "clause", "offset": [1075, 1091]}, {"key": "n\u00e1bor-subjekt\u016f", "type": "clause", "offset": [1324, 1338]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [1359, 1385]}, {"key": "attachment-a", "type": "definition", "offset": [1414, 1426]}, {"key": "each-case", "type": "definition", "offset": [1467, 1476]}, {"key": "reduced-amount", "type": "definition", "offset": [1513, 1527]}, {"key": "related-to", "type": "clause", "offset": [1574, 1584]}, {"key": "the-database", "type": "definition", "offset": [1599, 1611]}, {"key": "by-sponsor", "type": "clause", "offset": [1656, 1666]}, {"key": "data-queries", "type": "clause", "offset": [1692, 1704]}, {"key": "satisfaction-of", "type": "clause", "offset": [1716, 1731]}, {"key": "other-applicable-conditions", "type": "clause", "offset": [1736, 1763]}, {"key": "material-breach-of-this-agreement", "type": "clause", "offset": [1787, 1820]}, {"key": "and-termination", "type": "clause", "offset": [1846, 1861]}, {"key": "except-to-the-extent", "type": "clause", "offset": [1885, 1905]}, {"key": "subject-safety", "type": "clause", "offset": [1917, 1931]}, {"key": "suspend-performance", "type": "clause", "offset": [1964, 1983]}, {"key": "not-limited", "type": "clause", "offset": [2033, 2044]}, {"key": "subject-enrollment", "type": "clause", "offset": [2049, 2067]}, {"key": "a-\u2587", "type": "clause", "offset": [3038, 3041]}], "samples": [{"hash": "14PbFvT8qB9", "uri": "/contracts/14PbFvT8qB9#termination-15", "label": "Clinical Trial Agreement", "score": 31.2404921173, "published": true}], "size": 9, "hash": "987b68b3e4999b25ca79f8ebb76ce2bc", "id": 1}, {"snippet": "Ukon\u010den\u00ed platnosti Quintiles and/or Sponsor may terminate this Agreement for any reason effective immediately upon written notice. Quintiles a/nebo Zadavatel jsou opr\u00e1vn\u011bni ukon\u010dit platnost t\u00e9to Smlouvy z jak\u00e9hokoli d\u016fvodu s okam\u017eitou \u00fa\u010dinnost\u00ed neprodlen\u011b na z\u00e1klad\u011b doru\u010den\u00ed p\u00edsemn\u00e9ho ozn\u00e1men\u00ed. The Site may terminate upon written notice of no less then sixty (60) days to the other Party if circumstances beyond the Site\u2019s reasonable control prevent completion of the Study, or if it reasonably determines that it is unsafe to continue the Study. Upon receipt of notice of termination, the Site shall immediately cease any subject recruitment, follow the specified termination procedures, ensure that any required subject follow-up procedures are completed, and make all reasonable efforts to minimize further costs, and Quintiles shall make a final payment on a completed visit per subject basis visits or milestones properly performed pursuant to this Agreement in the amounts specified in Attachment A; If a material breach of this Agreement appears to have occurred and termination may be required, then, except to the extent that Study Subject safety may be jeopardized, Quintiles and/or Sponsor may suspend performance of all or part of this Agreement, including, but not limited to, subject enrollment. M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed je opr\u00e1vn\u011bno ukon\u010dit platnost t\u00e9to Smlouvy p\u00edsemn\u00fdm ozn\u00e1men\u00edm zaslan\u00fdm druh\u00e9 smluvn\u00ed Stran\u011b nejm\u00e9n\u011b \u0161edes\u00e1t (60) dn\u016f p\u0159edem v p\u0159\u00edpad\u011b, \u017ee okolnosti, je\u017e jsou svoj\u00ed povahou mimo mo\u017enost ovlivn\u011bn\u00ed ze strany M\u00edsta prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed, zabr\u00e1n\u00ed dokon\u010den\u00ed Studie, nebo v p\u0159\u00edpad\u011b, \u017ee M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed d\u016fvodn\u011b usoud\u00ed, \u017ee pokra\u010dov\u00e1n\u00ed ve Studii nen\u00ed bezpe\u010dn\u00e9. V n\u00e1vaznosti na doru\u010den\u00ed ozn\u00e1men\u00ed o ukon\u010den\u00ed platnosti M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed neprodlen\u011b ukon\u010d\u00ed jak\u00fdkoli n\u00e1bor subjekt\u016f, bude jednat v souladu s definovan\u00fdmi postupy pro ukon\u010den\u00ed, zajist\u00ed, \u017ee ve vztahu k subjekt\u016fm Studie budou dokon\u010deny jak\u00e9koli procesy kontroln\u00ed povahy, a vyvinou nezbytn\u00e9 \u00fasil\u00ed za \u00fa\u010delem limitace jak\u00fdchkoli dal\u0161\u00edch n\u00e1klad\u016f, p\u0159i\u010dem\u017e Quintiles provede z\u00e1v\u011bre\u010dnou \u00fahradu na z\u00e1klad\u011b uskute\u010dn\u011bn\u00fdch n\u00e1v\u0161t\u011bv jednotliv\u00fdch subjekt\u016f za n\u00e1v\u0161t\u011bvy a miln\u00edky, je\u017e byly \u0159\u00e1dn\u011b provedeny na z\u00e1klad\u011b a v souladu s touto Smlouvou, a to ve v\u00fd\u0161i \u010d\u00e1stek definovan\u00fdch v P\u0159\u00edloze A.V p\u0159\u00edpad\u011b, \u017ee dojde ke vzniku domn\u011bn\u00ed, \u017ee do\u0161lo k podstatn\u00e9mu poru\u0161en\u00ed t\u00e9to Smlouvy a m\u016f\u017ee tak doj\u00edt k ukon\u010den\u00ed platnosti t\u00e9to Smlouvy, pak s v\u00fdjimkou a \u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587 \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587 ohro\u017eena bezpe\u010dnost Subjekt\u016f studie, Quintiles a/nebo Zadavatel mohou p\u0159eru\u0161it napln\u011bn\u00ed cel\u00e9 \u010di \u010d\u00e1sti t\u00e9to Smlouvy, zejm\u00e9na v\u010detn\u011b za\u0159azov\u00e1n\u00ed Subjekt\u016f studie.", "snippet_links": [{"key": "ukon\u010den\u00ed-platnosti", "type": "clause", "offset": [0, 18]}, {"key": "for-any-reason", "type": "clause", "offset": [73, 87]}, {"key": "upon-written-notice", "type": "clause", "offset": [110, 129]}, {"key": "the-site", "type": "clause", "offset": [296, 304]}, {"key": "other-party", "type": "definition", "offset": [378, 389]}, {"key": "reasonable-control", "type": "clause", "offset": [425, 443]}, {"key": "completion-of-the-study", "type": "clause", "offset": [452, 475]}, {"key": "notice-of-termination", "type": "clause", "offset": [565, 586]}, {"key": "subject-recruitment", "type": "clause", "offset": [625, 644]}, {"key": "termination-procedures", "type": "clause", "offset": [667, 689]}, {"key": "efforts-to-minimize", "type": "clause", "offset": [784, 803]}, {"key": "further-costs", "type": "clause", "offset": [804, 817]}, {"key": "final-payment", "type": "definition", "offset": [846, 859]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [939, 965]}, {"key": "attachment-a", "type": "definition", "offset": [994, 1006]}, {"key": "material-breach-of-this-agreement", "type": "clause", "offset": [1013, 1046]}, {"key": "and-termination", "type": "clause", "offset": [1072, 1087]}, {"key": "except-to-the-extent", "type": "clause", "offset": [1111, 1131]}, {"key": "subject-safety", "type": "clause", "offset": [1143, 1157]}, {"key": "suspend-performance", "type": "clause", "offset": [1207, 1226]}, {"key": "not-limited", "type": "clause", "offset": [1276, 1287]}, {"key": "subject-enrollment", "type": "clause", "offset": [1292, 1310]}, {"key": "prov\u00e1d\u011bn\u00ed-klinick\u00e9ho-hodnocen\u00ed", "type": "clause", "offset": [1318, 1348]}, {"key": "dokon\u010den\u00ed-studie", "type": "clause", "offset": [1600, 1616]}, {"key": "n\u00e1bor-subjekt\u016f", "type": "clause", "offset": [1849, 1863]}, {"key": "a-\u2587", "type": "clause", "offset": [2472, 2475]}], "samples": [{"hash": "73G0MKC83gP", "uri": "/contracts/73G0MKC83gP#termination-15", "label": "Clinical Trial Agreement", "score": 27.5441850509, "published": true}], "size": 9, "hash": "9c11dee5f884f75f3160c5d4d537a89c", "id": 2}, {"snippet": "Section 4.1 Early Termination of Agreement; Breach of Agreement 15 Section 4.2 Early Termination Notice 16 Section 4.3 Payment upon Early Termination 17", "snippet_links": [{"key": "section-41", "type": "clause", "offset": [0, 11]}, {"key": "early-termination-of-agreement", "type": "clause", "offset": [12, 42]}, {"key": "breach-of-agreement", "type": "clause", "offset": [44, 63]}, {"key": "section-42", "type": "clause", "offset": [67, 78]}, {"key": "notice-16", "type": "clause", "offset": [97, 106]}, {"key": "section-43", "type": "clause", "offset": [107, 118]}, {"key": "termination-17", "type": "clause", "offset": [138, 152]}], "samples": [{"hash": "5xlLuhucagY", "uri": "/contracts/5xlLuhucagY#termination-15", "label": "Tax Receivable Agreement (Cresco Labs Inc.)", "score": 32.0335386721, "published": true}, {"hash": "4mp4xNYX0NJ", "uri": "/contracts/4mp4xNYX0NJ#termination-15", "label": "Tax Receivable Agreement", "score": 25.462696783, "published": true}], "size": 5, "hash": "c50c2f6ec05e8715220dad1d85a41347", "id": 3}, {"snippet": "2.1 Sponsor may terminate this Agreement for any reason effective immediately upon written notice.", "snippet_links": [{"key": "for-any-reason", "type": "clause", "offset": [41, 55]}, {"key": "upon-written-notice", "type": "clause", "offset": [78, 97]}], "samples": [{"hash": "fQ4tjimWook", "uri": "/contracts/fQ4tjimWook#termination-15", "label": "Clinical Trial Agreement", "score": 28.8033741377, "published": true}, {"hash": "NyVkZfcZEc", "uri": "/contracts/NyVkZfcZEc#termination-15", "label": "Clinical Trial Agreement", "score": 28.7541015213, "published": true}, {"hash": "jpJxzCnx742", "uri": "/contracts/jpJxzCnx742#termination-15", "label": "Clinical Trial Agreement", "score": 28.0889912643, "published": true}], "size": 3, "hash": "760ba13f4b833ad60b4ad303d9a27491", "id": 4}, {"snippet": "Section 4.1 Early Termination of Agreement; Breach of Agreement 15 Section 4.2 Early Termination Notice 16 Section 4.3 Payment Upon Early Termination 17 ARTICLE V. SUBORDINATION AND LATE PAYMENTS 17 Section 5.1 Subordination 17 Section 5.2 Late Payments by the Corporation 18 ARTICLE VI. TAX MATTERS; CONSISTENCY; COOPERATION 18 Section 6.1 Participation in the Corporation\u2019s and the LLC\u2019s Tax Matters 18 Section 6.2 Consistency 18 Section 6.3 Cooperation 18 ARTICLE VII. MISCELLANEOUS 18 Section 7.1 Notices 18 Section 7.2 Counterparts 19 Section 7.3 Entire Agreement; No Third Party Beneficiaries 19 Section 7.4 Governing Law 20 Section 7.5 Severability 20 Section 7.6 Assignments; Amendments; Successors; No Waiver 20 Section 7.7 Titles and Subtitles 21 Section 7.8 Resolution of Disputes 21 Section 7.9 Reconciliation 22 Section 7.10 Withholding 22 Section 7.11 Admission of the Corporation into a Consolidated Group; Transfers of Corporate Assets 23 Section 7.12 Confidentiality 23 Section 7.13 Change in Law 24 Section 7.14 Interest Rate Limitation 24 Section 7.15 Independent Nature of Rights and Obligations 24 Section 7.16 LLC Agreement 25 Section 7.17 Rules of Construction 25 Exhibit A \u2013 Form of Joinder Agreement This TAX RECEIVABLE AGREEMENT, dated as of [ ] [ ], 2018, is hereby entered into by and among i3 Verticals, Inc., a Delaware corporation (the \u201cCorporation\u201d), i3 Verticals, LLC, a Delaware limited liability company (the \u201cLLC\u201d), and each of the Members from time to time party hereto. Capitalized terms used but not otherwise defined herein have the respective meanings set forth in Section 1.1.", "snippet_links": [{"key": "section-41", "type": "clause", "offset": [0, 11]}, {"key": "early-termination-of-agreement", "type": "clause", "offset": [12, 42]}, {"key": "breach-of-agreement", "type": "clause", "offset": [44, 63]}, {"key": "section-42", "type": "clause", "offset": [67, 78]}, {"key": "notice-16", "type": "clause", "offset": [97, 106]}, {"key": "section-43", "type": "clause", "offset": [107, 118]}, {"key": "termination-17", "type": "clause", "offset": [138, 152]}, {"key": "subordination-and-late-payments", "type": "clause", "offset": [164, 195]}, {"key": "section-51", "type": "clause", "offset": [199, 210]}, {"key": "section-52", "type": "clause", "offset": [228, 239]}, {"key": "late-payments-by-the-corporation", "type": "clause", "offset": [240, 272]}, {"key": "tax-matters", "type": "definition", "offset": [288, 299]}, {"key": "section-61", "type": "clause", "offset": [329, 340]}, {"key": "the-llc", "type": "clause", "offset": [380, 387]}, {"key": "section-62", "type": "clause", "offset": [405, 416]}, {"key": "section-63", "type": "clause", "offset": [432, 443]}, {"key": "article-vii", "type": "clause", "offset": [459, 470]}, {"key": "miscellaneous-18", "type": "clause", "offset": [472, 488]}, {"key": "section-72", "type": "clause", "offset": [512, 523]}, {"key": "section-73", "type": "clause", "offset": [540, 551]}, {"key": "entire-agreement", "type": "clause", "offset": [552, 568]}, {"key": "no-third-party-beneficiaries", "type": "clause", "offset": [570, 598]}, {"key": "section-74", "type": "clause", "offset": [602, 613]}, {"key": "governing-law", "type": "definition", "offset": [614, 627]}, {"key": "section-75", "type": "clause", "offset": [631, 642]}, {"key": "section-76", "type": "clause", "offset": [659, 670]}, {"key": "no-waiver", "type": "definition", "offset": [708, 717]}, {"key": "section-77", "type": "clause", "offset": [721, 732]}, {"key": "titles-and-subtitles", "type": "clause", "offset": [733, 753]}, {"key": "section-78", "type": "clause", "offset": [757, 768]}, {"key": "resolution-of-disputes", "type": "definition", "offset": [769, 791]}, {"key": "section-79", "type": "clause", "offset": [795, 806]}, {"key": "section-710", "type": "definition", "offset": [825, 837]}, {"key": "withholding-22", "type": "clause", "offset": [838, 852]}, {"key": "admission-of-the-corporation-into-a-consolidated-group", "type": "clause", "offset": [866, 920]}, {"key": "transfers-of-corporate-assets", "type": "clause", "offset": [922, 951]}, {"key": "change-in-law", "type": "definition", "offset": [1000, 1013]}, {"key": "interest-rate-limitation", "type": "clause", "offset": [1030, 1054]}, {"key": "independent-nature-of-rights-and-obligations", "type": "clause", "offset": [1071, 1115]}, {"key": "section-716", "type": "clause", "offset": [1119, 1131]}, {"key": "llc-agreement", "type": "definition", "offset": [1132, 1145]}, {"key": "section-717", "type": "clause", "offset": [1149, 1161]}, {"key": "rules-of-construction", "type": "clause", "offset": [1162, 1183]}, {"key": "exhibit-a", "type": "clause", "offset": [1187, 1196]}, {"key": "form-of-joinder-agreement", "type": "clause", "offset": [1199, 1224]}, {"key": "tax-receivable-agreement", "type": "definition", "offset": [1230, 1254]}, {"key": "dated-as-of", "type": "definition", "offset": [1256, 1267]}, {"key": "entered-into", "type": "clause", "offset": [1293, 1305]}, {"key": "delaware-corporation", "type": "clause", "offset": [1341, 1361]}, {"key": "a-delaware-limited-liability-company", "type": "clause", "offset": [1402, 1438]}, {"key": "the-members", "type": "clause", "offset": [1464, 1475]}, {"key": "from-time-to-time", "type": "clause", "offset": [1476, 1493]}, {"key": "party-hereto", "type": "definition", "offset": [1494, 1506]}, {"key": "capitalized-terms-used-but", "type": "clause", "offset": [1508, 1534]}], "samples": [{"hash": "c42aCnXLFmp", "uri": "/contracts/c42aCnXLFmp#termination-15", "label": "Tax Receivable Agreement (I3 Verticals, Inc.)", "score": 29.3942505133, "published": true}, {"hash": "8wVQGthI6fT", "uri": "/contracts/8wVQGthI6fT#termination-15", "label": "Tax Receivable Agreement (I3 Verticals, Inc.)", "score": 29.3531827515, "published": true}], "size": 2, "hash": "452f8d8bd3a3db44d336e46fc367a6d2", "id": 5}, {"snippet": "The Minister may at any time prior to the expiry of the Term, immediately terminate this PLA, without cause, upon written notice to the Manufacturer.", "snippet_links": [{"key": "the-minister", "type": "clause", "offset": [0, 12]}, {"key": "at-any-time", "type": "clause", "offset": [17, 28]}, {"key": "prior-to-the", "type": "clause", "offset": [29, 41]}, {"key": "expiry-of-the-term", "type": "clause", "offset": [42, 60]}, {"key": "without-cause", "type": "definition", "offset": [94, 107]}, {"key": "the-manufacturer", "type": "definition", "offset": [132, 148]}], "samples": [{"hash": "75pzYJGCG4X", "uri": "/contracts/75pzYJGCG4X#termination-15", "label": "Product Listing Agreement", "score": 26.5181382615, "published": true}, {"hash": "bh8305XN6hF", "uri": "/contracts/bh8305XN6hF#termination-15", "label": "Product Listing Agreement", "score": 26.453798768, "published": true}], "size": 2, "hash": "536edaf0700577fe427d22838e3e2d3b", "id": 6}, {"snippet": "Compensation 15", "snippet_links": [], "samples": [{"hash": "fIplYP2KR5C", "uri": "/contracts/fIplYP2KR5C#termination-15", "label": "Framework Agreement", "score": 31.09314467, "published": true}], "size": 1, "hash": "cc51b3392fba6f98ed749041eb42eee6", "id": 7}, {"snippet": "Breach Either of the Parties hereto may terminate this Contract, if the other Party is in breach of any material provisions hereof, including, but not limited to, the Articles 3, 4 and 7 of this Contract, and the breach is not fixed within 30 (thirty) calendar days after a written notice requiring such a breach to be remedied is given to the Party in breach, by submission of a written notice before 15 (fifteen) calendar days of the Contract termination.", "snippet_links": [{"key": "the-parties-hereto", "type": "clause", "offset": [17, 35]}, {"key": "this-contract", "type": "clause", "offset": [50, 63]}, {"key": "other-party", "type": "definition", "offset": [72, 83]}, {"key": "breach-of-any", "type": "clause", "offset": [90, 103]}, {"key": "material-provisions", "type": "definition", "offset": [104, 123]}, {"key": "not-limited", "type": "clause", "offset": [147, 158]}, {"key": "articles-3", "type": "clause", "offset": [167, 177]}, {"key": "days-after", "type": "definition", "offset": [261, 271]}, {"key": "written-notice", "type": "definition", "offset": [274, 288]}, {"key": "party-in-breach", "type": "definition", "offset": [344, 359]}, {"key": "submission-of", "type": "clause", "offset": [364, 377]}, {"key": "contract-termination", "type": "definition", "offset": [436, 456]}], "samples": [{"hash": "e6HBWZODitA", "uri": "/contracts/e6HBWZODitA#termination-15", "label": "Contract for Supply of Tooling", "score": 30.3023643559, "published": true}], "size": 1, "hash": "b974372d231da5b5b35d91e99618f92b", "id": 8}, {"snippet": "2. Vypovedanie Quintiles may terminate this Agreement for any reason effective immediately upon written notice. The Institution may terminate upon written notice if circumstances beyond the Institution\u2019s reasonable control prevent completion of the Study, or if it reasonably determines that it is unsafe to continue the Study. Upon receipt of notice of termination, the Institution shall make all reasonable efforts to minimize further costs, and Quintiles shall make a final payment for visits or milestones properly performed pursuant to this Agreement in the amounts specified in Attachment A; provided, however, Quintiles m\u00f4\u017ee t\u00fato zmluvu vypoveda\u0165 z ak\u00e9hoko\u013evek d\u00f4vodu s okam\u017eitou \u00fa\u010dinnos\u0165ou p\u00edsomnou v\u00fdpove\u010fou. Zdravotn\u00edcke zariadenie m\u00f4\u017ee t\u00fato zmluvu vypoveda\u0165 p\u00edsomnou v\u00fdpove\u010fou, ak mu okolnosti mimo jeho primeranej kontroly zabra\u0148uj\u00fa v dokon\u010den\u00ed sk\u00fa\u0161ania, alebo ak dospeje k od\u00f4vodnen\u00e9mu z\u00e1veru, \u017ee pokra\u010dovanie v sk\u00fa\u0161an\u00ed nie je bezpe\u010dn\u00e9. Po prevzat\u00ed p\u00edsomnej v\u00fdpovede zdravotn\u00edcke zariadenie vynalo\u017e\u00ed primeran\u00e9 \u00fasilie na minimalizovanie \u010fal\u0161\u00edch n\u00e1kladov. \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587 n\u00e1v\u0161tevy alebo v\u00fdkony riadne vykonan\u00e9 v s\u00falade s touto MYL-GAI-3002 CTA-Institution Slovakia v1.0 25Apr14 Updated from English to Slovak by RR Donnelley on 21-Aug- 2014 PI \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 MD, Protocol MYL-GAI-3002 Project Code WVA98641 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587 z 23 that ten percent (10%) of this final payment will be withheld until final acceptance by Sponsor of all CRF pages and all data clarifications issued and satisfaction of all other applicable conditions set forth herein. If a material breach of this Agreement appears to have occurred and termination may be required, then, except to the extent that Study Subject safety may be jeopardized, Quintiles may suspend performance of all or part of this Agreement, including, but not limited to, subject enrollment.", "snippet_links": [{"key": "for-any-reason", "type": "clause", "offset": [54, 68]}, {"key": "upon-written-notice", "type": "clause", "offset": [91, 110]}, {"key": "the-institution", "type": "clause", "offset": [112, 127]}, {"key": "reasonable-control", "type": "clause", "offset": [204, 222]}, {"key": "completion-of-the-study", "type": "clause", "offset": [231, 254]}, {"key": "notice-of-termination", "type": "clause", "offset": [344, 365]}, {"key": "institution-shall", "type": "clause", "offset": [371, 388]}, {"key": "efforts-to-minimize", "type": "clause", "offset": [409, 428]}, {"key": "further-costs", "type": "clause", "offset": [429, 442]}, {"key": "payment-for", "type": "clause", "offset": [477, 488]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [529, 555]}, {"key": "attachment-a", "type": "definition", "offset": [584, 596]}, {"key": "by-sponsor", "type": "clause", "offset": [1449, 1459]}, {"key": "satisfaction-of", "type": "clause", "offset": [1516, 1531]}, {"key": "other-applicable-conditions", "type": "clause", "offset": [1536, 1563]}, {"key": "material-breach-of-this-agreement", "type": "clause", "offset": [1587, 1620]}, {"key": "and-termination", "type": "clause", "offset": [1646, 1661]}, {"key": "except-to-the-extent", "type": "clause", "offset": [1685, 1705]}, {"key": "subject-safety", "type": "clause", "offset": [1717, 1731]}, {"key": "suspend-performance", "type": "clause", "offset": [1766, 1785]}, {"key": "not-limited", "type": "clause", "offset": [1835, 1846]}, {"key": "subject-enrollment", "type": "clause", "offset": [1851, 1869]}], "samples": [{"hash": "5kydkGpjeEK", "uri": "/contracts/5kydkGpjeEK#termination-15", "label": "Clinical Trial Agreement", "score": 25.8643021899, "published": true}], "size": 1, "hash": "ea7ad31f85b2d07ef391e6e1be384b03", "id": 9}, {"snippet": "2 Ukon\u010den\u00ed platnosti IQVIA and/or Sponsor may terminate this Agreement for any reason effective immediately upon written notice. IQVIA a/nebo Zadavatel jsou opr\u00e1vn\u011bni ukon\u010dit platnost t\u00e9to Smlouvy z jak\u00e9hokoli d\u016fvodu s okam\u017eitou \u00fa\u010dinnost\u00ed neprodlen\u011b na z\u00e1klad\u011b doru\u010den\u00ed p\u00edsemn\u00e9ho ozn\u00e1men\u00ed. The Site may terminate upon written notice if at any time in the Investigator\u2019s professional judgment, a material adverse safety concern M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed je opr\u00e1vn\u011bno ukon\u010dit platnost t\u00e9to Smlouvy p\u00edsemn\u00fdm ozn\u00e1men\u00edm pokud kdykoli, na for the Study Subjects makes continued testing inadvisable. The Institution may terminate this Agreement in writing if, as a result of a hindrance beyond the control of the Institution, the Institution is rendered long-term incapable to complete the Study, without its main operation being hindered, which is the provision of healthcare services. The notice period shall be 30 days and shall start on the day following the day of its receipt by Sponsor, IQVIA and the the Investigator. Upon notice of termination or upon notice of suspension of the Study or this Agreement, Site shall immediately cease enrollment of subjects into the Study and, at the election of IQVIA shall (a) either (i) terminate the Agreement with respect to the enrolled subjects in an orderly and prompt manner and pursuant to consultation with IQVIA and Sponsor, including any required follow-up treatment with previously enrolled subjects, or (ii) transfer the enrolled subjects to another clinical site in accordance with IQVIA\u2019 instructions. Sponsor or its designee shall have the right to assume full control of the terminated Study and Site shall turn over all Study Documentation and materials in its possession associated with the Study, as expeditiously as possible, and shall provide such other assistance as is necessary to ensure a smooth and orderly transition of the Study without any disruption of the Protocol and (b) Site shall make all reasonable efforts to minimize further costs, and IQVIA shall make a final payment for visits or milestones properly performed pursuant to this Agreement in the amounts specified in Attachment A. z\u00e1klad\u011b odborn\u00e9ho \u00fasudku Hlavn\u00edho zkou\u0161ej\u00edc\u00edho, z\u00e1va\u017en\u00e9 obavy o bezpe\u010dnost Subjekt\u016f studie zp\u016fsob\u00ed, \u017ee dal\u0161\u00ed testov\u00e1n\u00ed bude ne\u017e\u00e1douc\u00ed. Zdravotnick\u00e9 za\u0159\u00edzen\u00ed je opr\u00e1vn\u011bno ukon\u010dit tuto smlouvu p\u00edsemnou v\u00fdpov\u011bd\u00ed, jestli\u017ee v d\u016fsledku vzniku p\u0159ek\u00e1\u017eky, je\u017e nastala nez\u00e1visle na jeho v\u016fli, nebude Zdravotnick\u00e9 za\u0159\u00edzen\u00ed dlouhodob\u011b schopno dokon\u010dit Studii, ani\u017e by t\u00edm nebyla negativn\u011b ovlivn\u011bna jeho hlavn\u00ed \u010dinnost, kterou je poskytov\u00e1n\u00ed zdravotn\u00ed p\u00e9\u010de. V\u00fdpov\u011bdn\u00ed lh\u016fta \u010din\u00ed 30 dn\u016f a po\u010d\u00edn\u00e1 b\u011b\u017eet dnem n\u00e1sleduj\u00edc\u00edm po dni doru\u010den\u00ed t\u00e9to v\u00fdpov\u011bdi Zadavateli, IQVIA a Zkou\u0161ej\u00edc\u00edmu. Po ozn\u00e1men\u00ed o ukon\u010den\u00ed platnosti, odesl\u00e1n\u00ed v\u00fdpov\u011bdi ze strany M\u00edsta prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed nebo ozn\u00e1men\u00ed o pozastaven\u00ed Studie nebo t\u00e9to Smlouvy M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed okam\u017eit\u011b p\u0159estane za\u0159azovat Subjekty do Studie a podle rozhodnut\u00ed spole\u010dnosti IQVIA (a) bu\u010f okam\u017eit\u011b ukon\u010d\u00ed platnost Smlouvy ve vztahu k ji\u017e za\u0159azen\u00fdm Subjekt\u016fm, a to \u0159\u00e1dn\u011b a neprodlen\u011b, na z\u00e1klad\u011b konzultace s IQVIA a Zadavatelem, v\u010detn\u011b pot\u0159ebn\u00e9 n\u00e1sledn\u00e9 l\u00e9\u010dby d\u0159\u00edve za\u0159azen\u00fdch Subjekt\u016f, nebo (ii) p\u0159evede za\u0159azen\u00e9 Subjekty na jin\u00e9 klinick\u00e9 pracovi\u0161t\u011b podle pokyn\u016f spole\u010dnosti IQVIA. Zadavatel nebo jeho pov\u011b\u0159en\u00fd z\u00e1stupce budou opr\u00e1vn\u011bni p\u0159evz\u00edt plnou kontrolu nad ukon\u010denou Studi\u00ed, a M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed jim p\u0159ed\u00e1 co mo\u017en\u00e1 nejrychleji ve\u0161kerou Studijn\u00ed dokumentaci a materi\u00e1ly souvisej\u00edc\u00ed se Studi\u00ed, kter\u00e9 m\u00e1 ve sv\u00e9m dr\u017een\u00ed, a poskytne jakoukoli jinou sou\u010dinnost pro zaji\u0161t\u011bn\u00ed snadn\u00e9ho a \u0159\u00e1dn\u00e9ho p\u0159eveden\u00ed Studie bez naru\u0161en\u00ed Protokolu, a (b) M\u00edsto prov\u00e1d\u011bn\u00ed klinick\u00e9ho hodnocen\u00ed vyvine nezbytn\u00e9 \u00fasil\u00ed za \u00fa\u010delem limitace jak\u00fdchkoli dal\u0161\u00edch n\u00e1klad\u016f, p\u0159i\u010dem\u017e IQVIA provede z\u00e1v\u011bre\u010dnou \u00fahradu za n\u00e1v\u0161t\u011bvy a miln\u00edky, je\u017e byly \u0159\u00e1dn\u011b provedeny na z\u00e1klad\u011b a v souladu s touto Smlouvou, a to ve v\u00fd\u0161i \u010d\u00e1stek definovan\u00fdch v P\u0159\u00edloze A.", "snippet_links": [{"key": "ukon\u010den\u00ed-platnosti-iqvia", "type": "clause", "offset": [2, 26]}, {"key": "for-any-reason", "type": "clause", "offset": [71, 85]}, {"key": "upon-written-notice", "type": "clause", "offset": [108, 127]}, {"key": "the-site", "type": "clause", "offset": [290, 298]}, {"key": "at-any-time", "type": "clause", "offset": [336, 347]}, {"key": "the-investigator", "type": "clause", "offset": [351, 367]}, {"key": "professional-judgment", "type": "clause", "offset": [370, 391]}, {"key": "material-adverse", "type": "definition", "offset": [395, 411]}, {"key": "safety-concern", "type": "definition", "offset": [412, 426]}, {"key": "prov\u00e1d\u011bn\u00ed-klinick\u00e9ho-hodnocen\u00ed", "type": "clause", "offset": [433, 463]}, {"key": "study-subjects", "type": "definition", "offset": [552, 566]}, {"key": "the-institution", "type": "clause", "offset": [604, 619]}, {"key": "agreement-in-writing", "type": "clause", "offset": [639, 659]}, {"key": "control-of-the", "type": "clause", "offset": [702, 716]}, {"key": "complete-the", "type": "clause", "offset": [781, 793]}, {"key": "provision-of", "type": "clause", "offset": [857, 869]}, {"key": "healthcare-services", "type": "definition", "offset": [870, 889]}, {"key": "the-notice-period", "type": "clause", "offset": [891, 908]}, {"key": "the-day", "type": "definition", "offset": [945, 952]}, {"key": "following-the", "type": "definition", "offset": [953, 966]}, {"key": "day-of", "type": "clause", "offset": [967, 973]}, {"key": "by-sponsor", "type": "clause", "offset": [986, 996]}, {"key": "upon-notice-of-termination", "type": "clause", "offset": [1030, 1056]}, {"key": "suspension-of-the-study", "type": "clause", "offset": [1075, 1098]}, {"key": "enrollment-of-subjects", "type": "clause", "offset": [1147, 1169]}, {"key": "election-of", "type": "clause", "offset": [1197, 1208]}, {"key": "terminate-the-agreement", "type": "clause", "offset": [1236, 1259]}, {"key": "with-respect-to", "type": "clause", "offset": [1260, 1275]}, {"key": "previously-enrolled", "type": "clause", "offset": [1431, 1450]}, {"key": "clinical-site", "type": "definition", "offset": [1511, 1524]}, {"key": "in-accordance-with", "type": "definition", "offset": [1525, 1543]}, {"key": "to-assume", "type": "clause", "offset": [1610, 1619]}, {"key": "full-control", "type": "clause", "offset": [1620, 1632]}, {"key": "turn-over", "type": "definition", "offset": [1672, 1681]}, {"key": "study-documentation", "type": "definition", "offset": [1686, 1705]}, {"key": "associated-with", "type": "definition", "offset": [1738, 1753]}, {"key": "other-assistance", "type": "definition", "offset": [1818, 1834]}, {"key": "to-ensure", "type": "clause", "offset": [1851, 1860]}, {"key": "orderly-transition", "type": "clause", "offset": [1874, 1892]}, {"key": "the-protocol", "type": "clause", "offset": [1932, 1944]}, {"key": "efforts-to-minimize", "type": "clause", "offset": [1984, 2003]}, {"key": "further-costs", "type": "clause", "offset": [2004, 2017]}, {"key": "payment-for", "type": "clause", "offset": [2048, 2059]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [2100, 2126]}, {"key": "zdravotnick\u00e9-za\u0159\u00edzen\u00ed", "type": "clause", "offset": [2304, 2325]}, {"key": "pozastaven\u00ed-studie", "type": "clause", "offset": [2855, 2873]}, {"key": "platnost-smlouvy", "type": "clause", "offset": [3037, 3053]}, {"key": "naru\u0161en\u00ed-protokolu", "type": "clause", "offset": [3666, 3684]}], "samples": [{"hash": "iPnyrVZssD7", "uri": "/contracts/iPnyrVZssD7#termination-15", "label": "Clinical Trial Agreement", "score": 29.0907977337, "published": true}], "size": 1, "hash": "2746ce07535b63861f2ff6d627c4b3af", "id": 10}], "next_curs": "ClcSUWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjMLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ihd0ZXJtaW5hdGlvbi0xNSMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"parents": [["no-conflicts", "No Conflicts"], ["term-termination-15", "Term Termination 15"], ["term-termination-15-platnost-a-ukon\u010den\u00ed-platnosti", "Term & Termination 15. Platnost a Ukon\u010den\u00ed platnosti"], ["intellectual-property-4-du\u0161evn\u00ed-vlastnictv\u00ed", "INTELLECTUAL PROPERTY 4 DU\u0160EVN\u00cd VLASTNICTV\u00cd"], ["payment-2", "Payment 2"]], "children": [["", ""], ["no-waiver-enforceability", "No Waiver/Enforceability"], ["surrender-of-the-leased-premises", "Surrender of the Leased Premises"], ["termination-of-study-at-the-institution-upon-notice", "Termination of Study at the Institution Upon Notice"], ["entire-agreement", "Entire Agreement"]], "title": "Termination 15", "size": 49, "id": "termination-15", "related": [["termination-for-cause-by-city", "TERMINATION FOR CAUSE BY CITY", "TERMINATION FOR CAUSE BY CITY"], ["termination-for-cause-by-company", "Termination for Cause by Company", "Termination for Cause by Company"], ["cfr-part-200-termination-termination-for-cause", "CFR PART 200 Termination Termination for cause", "CFR PART 200 Termination Termination for cause"], ["termination-for-cause-by-the-district", "Termination for Cause by The District", "Termination for Cause by The District"], ["termination-for-cause-or-voluntary-termination", "Termination for Cause or Voluntary Termination", "Termination for Cause or Voluntary Termination"]], "related_snippets": [], "updated": "2025-07-07T12:36:13+00:00", "also_ask": [], "drafting_tip": "", "explanation": "The 'Termination 15' clause defines the conditions and procedures under which a contract may be ended before its natural expiration. Typically, this clause outlines the specific events or breaches that can trigger termination, such as non-performance, insolvency, or mutual agreement, and may require written notice or a cure period before termination becomes effective. Its core practical function is to provide both parties with a clear and agreed-upon mechanism for ending the contractual relationship, thereby managing risk and preventing disputes over how and when a contract can be lawfully terminated."}, "json": true, "cursor": ""}}